EXECUTIVE OFFICE OF THE PRESIDENT OFFICE OF MANAGEMENT AND BUDGET WASHINGTON, D.C. 20503
STATEMENT OF ADMINISTRATION POLICY (THIS STATEMENT HAS BEEN COORDINATED BY OMB WITH THE CONCERNED AGENCIES.)
November 8, 1997
H.R. 2610 - National Narcotics Leadership Act of 1997
(Hatch (R) Utah and Biden (D) Delaware)
The Administration strongly supports reauthorization for the Office of National
Drug Control Policy (ONDCP) and has no objection to Senate passage of the bill
as reported by the Senate Judiciary Committee. The bill reauthorizes ONDCP,
and gives the Office additional needed authority to deal with the drug problem
in America. The Senate version of H.R. 2610 incorporates the Performance
Measurement System included in the Administration's bill to reauthorize ONDCP,
which will establish ambitious yet achievable targets against which the
progress of the National Drug Control Strategy will be measured. The bill also
endorses long-term planning with a ten-year strategy and five-year budgets,
enabling ONDCP to make the necessary commitment to address the complex problem
of drug abuse. The Administration applauds the Senate for pursuing legislation
that provides for ongoing evaluation of the Strategy without specifying
numerical statutory targets.
The Administration, however, will seek amendments to:
Delete the provisions designating ONDCP as "the representative of the
President in appearing before Congress on all issues relating to the National
Drug Control Program," "the primary spokesperson of the President on drug
issues," and "the chief drug policy control spokesman for the President."
These designations raise constitutional concerns by interfering with the
President's discretion to make such determinations.
Delete the provisions specifying the membership, chairmanship, and
frequency of meetings of the proposed President's Council on
Counter-Narcotics. These provisions inappropriately micromanage the
deliberative process of the Executive branch. In addition, designating members
of this proposed Council, whose positions are not established by statute (e.g.,
the White House Counsel), raises additional constitutional concerns.
Change the date for submission of the Performance Measurement System to
the Congress from November 1, 1997, to early 1998 to permit the System to be
developed in conjunction with the agency performance plans required by the
Government Performance and Results Act of 1993.
Delete the provisions requiring ONDCP to provide to Congress all budgetary
requests of drug control program agencies as part of its presentation of the
President's annual drug strategy. These provisions interfere with Executive
branch discretion to formulate and present a cohesive strategy by requiring the
submission to Congress of draft proposals that were rejected in the policy and
budgetary formulation process.
Revise the provision concerning the Parents Advisory Council on Youth Drugs
to have the Council report to the Director of ONDCP instead of the President.
In addition, the authority of the Council to compel agencies to provide
requested information should be revised to grant the head of an agency
discretion to withhold information such as medical records, confidential
personnel records, investigative files, and other materials that need to be
protected. The Administration also recommends that the Director of ONDCP serve
as the Executive Director of the Council to avoid the need to create a new and
unnecessary bureaucracy. Finally, the legislation should clarify in which
branch of government the Council resides so that the appropriate body of ethics
law can be applied to the Council members.
Delete Section 3, "Drug Interdiction", which establishes measures of
success that conflict with ONDCP's performance measurement system and the 1997
National Drug Control Strategy.
Reauthorize ONDCP for 12 years. Although the bill, as a whole, supports
long-range planning with a ten-year strategy and five-year budgets, the
four-year reauthorization period is inadequate to implement this long-term
Delete section 4(b), which would require the President to submit a report
to Congress describing consultations with Western Hemisphere leaders about ways
to improve multi-lateral cooperation in anti-drug efforts. This requirement
would interfere with the President's authority to conduct the foreign relations
of the United States.
Delete the provision that would permit the Director of ONDCP to require the
National Drug Intelligence Center and the El Paso Intelligence Center to
undertake specific tasks or projects in support of the National Drug Control
Strategy. This provision would inappropriately interfere with the authority
and ability of the Attorney General to manage these components of the
Department of Justice.
The Administration's review of the bill is continuing, and any additional
concerns will be communicated as they are identified.